Search Results - "Schjesvold, Fredrik H."

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis by Schjesvold, Fredrik H, Richardson, Paul G, Facon, Thierry, Alegre, Adrián, Spencer, Andrew, Jurczyszyn, Artur, Sunami, Kazutaka, Frenzel, Laurent, Min, Chang-Ki, Guillonneau, Sophie, Lin, Peggy L, Le-Guennec, Solenn, Campana, Frank, van de Velde, Helgi, Bensfia, Samira, Bringhen, Sara

Get full text

Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA by Schjesvold, Fredrik H, Bakker, Nicolaas A, Sonneveld, Pieter

Get full text

Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study by Pour, Luděk, Szarejko, Monika, Bila, Jelena, Schjesvold, Fredrik H, Spicka, Ivan, Maisnar, Vladimir, Jurczyszyn, Artur, Grudeva-Popova, Zhanet, Hájek, Roman, Usenko, Ganna, Thuresson, Marcus, Norin, Stefan, Jarefors, Sara, Bakker, Nicolaas A, Richardson, Paul G, Mateos, Maria-Victoria

“…Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with…”
Get full text

Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study by Schjesvold, Fredrik H, Ludwig, Heinz, Delimpasi, Sossana, Robak, Pawel, Coriu, Daniel, Tomczak, Waldemar, Pour, Ludek, Spicka, Ivan, Dimopoulos, Meletios-Athanasios, Masszi, Tamas, Chernova, Natalia G, Sandberg, Anna, Thuresson, Marcus, Norin, Stefan, Bakker, Nicolaas A, Mateos, Maria-Victoria, Richardson, Paul G, Sonneveld, Pieter

Get full text

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm by Pawlyn, Charlotte, Schjesvold, Fredrik H., Cairns, David A., Wei, L. J., Davies, Faith, Nadeem, Omar, Abdulhaq, Haifaa, Mateos, Maria-Victoria, Laubach, Jacob, Weisel, Katja, Ludwig, Heinz, Rajkumar, S. Vincent, Sonneveld, Pieter, Jackson, Graham, Morgan, Gareth, Richardson, Paul G.

“…Measurement of overall survival (OS) remains the gold standard for interpreting the impact of new therapies for multiple myeloma in phase 3 trials. However, as…”
Get full text

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma by Kaufman, Jonathan L., Gasparetto, Cristina, Schjesvold, Fredrik H., Moreau, Philippe, Touzeau, Cyrille, Facon, Thierry, Boise, Lawrence H., Jiang, Yanwen, Yang, Xiaoqing, Dunbar, Fengjiao, Vishwamitra, Deeksha, Unger, Stefanie, Macartney, Tammy, Pesko, John, Yu, Yao, Salem, Ahmed Hamed, Ross, Jeremy A., Hong, Wan‐Jen, Maciag, Paulo C., Pauff, James M., Kumar, Shaji

“…Venetoclax (Ven) is a selective small‐molecule inhibitor of BCL‐2 that exhibits antitumoral activity against MM cells with t(11;14) translocation. We evaluated…”
Get full text

Melflufen for relapsed and refractory multiple myeloma by Oriol, Albert, Larocca, Alessandra, Leleu, Xavier, Hajek, Roman, Hassoun, Hani, Rodríguez-Otero, Paula, Paner, Agne, Schjesvold, Fredrik H, Gullbo, Joachim, Richardson, Paul G

“…The overall survival of patients with multiple myeloma has improved with the advent of novel agents; however, multiple myeloma remains incurable. Combinations…”
Get more information

Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study by Schjesvold, Fredrik H., Ludwig, Heinz, Mateos, Maria‐Victoria, Larocca, Alessandra, Abdulhaq, Haifaa, Norin, Stefan, Thuresson, Marcus, Bakker, Nicolaas A., Richardson, Paul G., Sonneveld, Pieter

“…Melphalan flufenamide (melflufen), a first‐in‐class alkylating peptide‐drug conjugate, plus dexamethasone demonstrated superior progression‐free survival…”
Get full text

Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies by Sonneveld, Pieter, Richardson, Paul G., Ludwig, Heinz, Dimopoulos, Meletios-Athanasios, Schjesvold, Fredrik H., Hájek, Roman, Abdulhaq, Haifaa, Thuresson, Marcus, Norin, Stefan, Bakker, Nicolaas A., Mateos, Maria-Victoria

“…Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone demonstrated superior progression-free survival (PFS)…”
Get full text

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial by Zweegman, Sonja, Stege, Claudia A M, Haukas, Einar, Schjesvold, Fredrik H, Levin, Mark-David, Waage, Anders, Leys, Rineke B L, Klein, Saskia K, Szatkowski, Damian, Axelsson, Per, Hieu Do, Trung, Knut-Bojanowska, Dorota, van der Spek, Ellen, Svirskaite, Asta, Klostergaard, Anja, Salomo, Morten, Blimark, Celine, Ypma, Paula F, Mellqvist, Ulf-Henrik, Poddighe, Pino J, Stevens-Kroef, Marian, van de Donk, Niels W C J, Sonneveld, Pieter, Hansson, Markus, van der Holt, Bronno, Abildgaard, Niels

Get full text

Indirect CD4+ T‐cell‐mediated elimination of MHC IINEG tumor cells is spatially restricted and fails to prevent escape of antigen‐negative cells by Tveita, Anders A., Schjesvold, Fredrik H., Sundnes, Olav, Haabeth, Ole Audun W., Haraldsen, Guttorm, Bogen, Bjarne

“…Tumor‐specific Th1 cells can activate tumor‐infiltrating macrophages that eliminate MHC class II negative (MHC IINEG) tumor cells. Activated M1‐like…”
Get full text

Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells by Tveita, Anders A, Schjesvold, Fredrik H, Sundnes, Olav, Haabeth, Ole Audun W, Haraldsen, Guttorm, Bogen, Bjarne

“…Tumor-specific Th1 cells can activate tumor-infiltrating macrophages that eliminate MHC class II negative (MHC II(NEG)) tumor cells. Activated M1-like…”
Get full text

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial by Schmitz, Alexander, Brøndum, Rasmus Froberg, Johnsen, Hans Erik, Mellqvist, Ulf-Henrik, Waage, Anders, Gimsing, Peter, Op Bruinink, Davine Hofste, van der Velden, Vincent, van der Holt, Bronno, Hansson, Markus, Andersen, Niels Frost, Frølund, Ulf Christian, Helleberg, Carsten, Schjesvold, Fredrik H, Ahlberg, Lucia, Gulbrandsen, Nina, Andreasson, Bjorn, Lauri, Birgitta, Haukas, Einar, Bødker, Julie Støve, Roug, Anne Stidsholt, Bøgsted, Martin, Severinsen, Marianne T, Gregersen, Henrik, Abildgaard, Niels, Sonneveld, Pieter, Dybkær, Karen

“…Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of…”
Get full text

Ixazomib‐Thalidomide‐Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long‐term Results of HOVON‐126/NMSG 21.13 by Groen, Kazimierz, Schjesvold, Fredrik H., Holt, Bronno, Levin, Mark‐David, Seefat, Maarten R., Hansson, Markus, Leys, Maria B.L., Regelink, Josien C., Waage, Anders, Szatkowski, Damian, Axelsson, Per, Hieu Do, Trung, Svirskaite, Asta, Spek, Ellen, Haukas, Einar, Knut‐Bojanowska, Dorota, Ypma, Paula F., Blimark, Cecilie H., Mellqvist, Ulf‐Henrik, Donk, Niels W.C.J., Sonneveld, Pieter, Klostergaard, Anja, Vangsted, Annette J., Abildgaard, Niels, Zweegman, Sonja

Get full text

Evolution of diagnostic workup and treatment for multiple myeloma 2013‐2019 by Schjesvold, Fredrik

“…Objective To evaluate changes in diagnostic and therapeutic approach in multiple myeloma among Norwegian hematologists in the current decade. Methods This…”
Get full text

OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma by Schjesvold, Fredrik, Robak, Pawel, Pour, Ludek, Aschan, Johan, Sonneveld, Pieter

“…Melflufen is a novel peptide–drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. It has emerged as a potential new multiple myeloma…”
Get full text

Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group by Terpos, Evangelos, Zamagni, Elena, Lentzsch, Suzanne, Drake, Matthew T, García-Sanz, Ramón, Abildgaard, Niels, Ntanasis-Stathopoulos, Ioannis, Schjesvold, Fredrik, de la Rubia, Javier, Kyriakou, Charalampia, Hillengass, Jens, Zweegman, Sonja, Cavo, Michele, Moreau, Philippe, San-Miguel, Jesus, Dimopoulos, Meletios A, Munshi, Nikhil, Durie, Brian G M, Raje, Noopur

“…In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of…”
Get full text

Melflufen in multiple myeloma: the conclusion matters - Authors' reply by Schjesvold, Fredrik H, Bakker, Nicolaas A, Sonneveld, Pieter

Get full text

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) - Renal Impairment (RI) Analysis by Robak, Tadeusz, Delimpasi, Sosana, Pour, Ludek, Masszi, Tamas, Spicka, Ivan, Legiec, Wojciech, Sonneveld, Pieter, Thuresson, Marcus, Larsson, Kajsa, Harmenberg, Johan, Schjesvold, Fredrik H.

“…Background: Despite the expansion of effective treatment options for multiple myeloma (MM), the disease regularly relapses and the majority still die from the…”
Get full text

OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Subgroup Analysis By Prior Alkylator Exposed/Refractory Status by Sonneveld, Pieter, Mateos, Maria-Victoria, Robak, Pawel J., Schjesvold, Fredrik H., Hajek, Roman, Richardson, Paul G., Harmenberg, Johan, Thuresson, Marcus, Byrne, Catriona, Dimopoulos, Meletios-Athanasios

“…Background: Most pts with MM will be exposed to alkylators throughout their disease course as part of a multidrug regimen or as high-dose melphalan (HDM)…”
Get full text